CHUGAI PHARMACEUTICAL CO., LTD.

Payments to Medical Institutions, Healthcare Professionals, etc.

  Chugai discloses information in accordance with Transparency Guidelines for Chugai Activities Involving Medical Institutions, etc., to ensure the transparency of its activities with medical institutions and thereby demonstrate to the wider community that its corporate activities are based on high ethical and moral standards.
  Funding provided to Japanese medical institutions and healthcare professionals for each fiscal year (January 1 to December 31) is disclosed in the following five categories:A. R&D expenses, etc., B. academic research support grants, C. manuscript authorship fees, etc., D. information provision-related expenses, and E. other expenses.

Fiscal Year 2017

A. R&D expenses, etc.

  The total annual amounts are given for the following six categories. Joint research expenses and commissioned research expenses are expenses for basic research, clinical research, etc., for which GCP, GVP, GPSP, or other official regulations are not applicable. Clinical study expenses (for new drug development), postmarketing clinical study expenses, ADR/infection case reporting expenses, and postmarketing surveillance expenses are expenses for clinical studies, ADR/infection case reporting, and postmarketing surveillance that are conducted in accordance with GCP, GVP, GPSP, or other official regulations.
  Expenses categorized as C. manuscript authorship fees, etc., are not included here.
Starting with payments made in 2016, expenses paid to CROs (Contract Research Organization) are generally not disclosed. However, payments made to medical institutions via CROs are disclosed as "expenses provided to medical institutions".

Category Total annual transfer of value
Joint research expenses 504,235,838(yen)
drug 10460g
active ingredients・reagent 3275mg
Commissioned research expenses 887,130,139(yen)
Clinical study expenses 3,513,397,561(yen)
Postmarketing clinical study expenses 987,512,908(yen)
ADR/infection case reporting expenses 22,873,152(yen)
Postmarketing surveillance expenses 83,391,189(yen)

《Payment of new contracts thereafter fiscal year 2016》

Category No. of payments for fiscal year Total annual transfer of value
Joint research expenses Clinical 24 13,794,900(yen)
drug 10045g
Other 67 328,658,269(yen)
drug 5923mg
active ingredients・reagent 3160mg
Commissioned research expenses Clinical - 0(yen)
Other 6 1,140,214,110(yen)
Clinical study expenses 318 1,829,166,712(yen)
Postmarketing clinical study expenses - 0(yen)
ADR/infection case reporting expenses 872 21,958,733(yen)
Postmarketing surveillance expenses 189 25,636,767(yen)
Other expenses - 166,041,334(yen)

B. Academic research support grants

  Donations, etc., provided to promote academic research or support research are classified in the following four categories, and the recipient of each donation is given. Scholarship donations are donations to university schools of medicine and medical institutions with associated research institutes, etc., and donations to fund research for which applications are made. Academic society donations are donations to academic societies, etc., to cover expenses for meetings and other activities. General donations are donations to foundations, etc. Expenses for co-hosting with academic societies are expenses incurred in co-hosting seminars, etc., with academic societies.

Category Total for fiscal year
Scholarship donations 1,508,240,000(yen)
Academic society donations 83,565,550(yen)
General donations 1,161,550,300(yen)
Expenses for co-hosting with academic societies 469,222,606(yen)

C. Manuscript authorship fees, etc.

  These are classified in the following three categories: lecture fees, manuscript authorship/editorship fees, and other commissioning fees, and the recipient for each payment is given. Other commissioning fees are consulting fees and compensation for commissioning that cannot be categorized in lecture fees or manuscript authorship/editorship fees.

Category Total for fiscal year
Lecture fees 866,889,861(yen)
Manuscript authorship/editorship fees 37,898,294(yen)
Other commissioning fees 339,671,862(yen)

D. Information provision-related expenses

  Expenses incurred for the provision of medical or pharmaceutical information on Chugai drugs to healthcare professionals are classified in three categories, and the total annual amount is given for each category. Speaking engagements and other meeting expenses cover accommodation and transportation expenses, venue fees, information exchange meeting expenses, honoraria for responsible persons, etc. The total annual amount and number of payments are given. Briefing meeting expenses cover allowances for light refreshments and lunches during medical office briefings by medical representatives, etc., about Chugai drugs. The total annual amount and number of payments are given. Medical and pharmaceutical-related literature provision expenses, etc., are expenses for medical and pharmaceutical books, promotional gifts, etc.
  Expenses categorized as C. manuscript authorship fees, etc., are not included here.

Category No. of payments for fiscal year Total for fiscal year
Speaking engagements and other meeting expenses 5,940 3,304,457,783(yen)
Briefing meeting expenses 29,905 633,682,925(yen)
Medical and pharmaceutical-related literature provision expenses, etc. - 261,887,691(yen)

E. Other expenses

  The total annual amount is given for expenses related to social conventions such as hospitality, congratulatory/condolence gifts, mid/end-of-year gifts, condolatory money, and floral arrangements for healthcare professionals. Hospitality-related expenses are for all participants including healthcare professionals and Chugai staff and include transportation expenses.
  Fees for participation in events held by medical institutions, etc., and expenses involving food and beverages for which healthcare professionals are individually responsible, are not included.

Category Total for fiscal year
Other expenses 173,575,692(yen)